Ultragenyx Pharmaceutical (RARE) Operating Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Operating Margin of 124.26% for Q1 2026, down 2139.0% year-over-year from 6.09% in Q1 2025, and down 127.37% on a QoQ basis from 54.65% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 11 years of Operating Margin data on file, last reported at 124.26% in Q1 2026.
- Quarterly Operating Margin fell 2139.0% year-over-year to 124.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 83.78% (up 326.0% YoY) and the FY2025 annual result came in at 79.49%, up 1622.0% from the prior year.
- Operating Margin fell to 124.26% in Q1 2026 per RARE's latest filing, from 54.65% in the prior quarter.
- Across five years, Operating Margin topped out at 54.65% in Q4 2025 and bottomed at 248.14% in Q3 2022.
- The 5-year median for Operating Margin is 124.26% (2026), against an average of 123.86%.
- The widest annual swing landed in 2022, when Operating Margin slumped 13812 bps; it then surged 10016 bps in 2023.
- Tracing RARE's Operating Margin over 5 years: stood at 140.91% in 2022, then jumped by 32 bps to 95.83% in 2023, then climbed by 22 bps to 74.28% in 2024, then increased by 26 bps to 54.65% in 2025, then plunged by 127 bps to 124.26% in 2026.
- Per Business Quant, the three latest RARE Operating Margin figures stand at 124.26% (Q1 2026), 54.65% (Q4 2025), and 106.85% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -124.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -124.26% |
| Dec 31, 2025 | -54.65% |
| Sep 30, 2025 | -106.85% |
| Jun 30, 2025 | -64.80% |
| Mar 31, 2025 | -102.88% |
| Dec 31, 2024 | -74.28% |
| Sep 30, 2024 | -94.62% |
| Jun 30, 2024 | -79.14% |
| Mar 31, 2024 | -151.93% |
| Dec 31, 2023 | -95.83% |
| Sep 30, 2023 | -147.98% |
| Jun 30, 2023 | -136.61% |
| Mar 31, 2023 | -153.34% |
| Dec 31, 2022 | -140.91% |
| Sep 30, 2022 | -248.14% |
| Jun 30, 2022 | -158.48% |
| Mar 31, 2022 | -170.93% |
| Dec 31, 2021 | -122.99% |
| Sep 30, 2021 | -110.02% |
| Jun 30, 2021 | -95.17% |
| Mar 31, 2021 | -107.22% |
| Dec 31, 2020 | -104.96% |
| Sep 30, 2020 | -61.76% |
| Jun 30, 2020 | -102.18% |
| Mar 31, 2020 | -332.33% |
| Dec 31, 2019 | -265.37% |
| Sep 30, 2019 | -457.49% |
| Jun 30, 2019 | -465.75% |
| Mar 31, 2019 | -545.97% |
| Dec 31, 2018 | -555.56% |
| Sep 30, 2018 | -762.10% |
| Jun 30, 2018 | -741.75% |
| Mar 31, 2018 | -903.69% |
| Dec 31, 2017 | -4,611.14% |
| Sep 30, 2017 | -42,279.29% |
| Dec 31, 2016 | -1,410,980.00% |
| Sep 30, 2016 | -59,263.96% |
| Jun 30, 2016 | -341,488.24% |